RECENT PAPERS
​
Jiang Q, Braun DA, Clauser KR, Ramesh V, Shirole NH, Duke-Cohan JE, Nabilsi N, Kramer NJ, Forman C, Lippincott IE, Klaeger S, Phulphagar KM, Chea V, Kim N, Vanasse AP, Saad E, Parsons T, Carr-Reynolds M, Carulli I, Pinjusic K, Jiang Y, Li R, Syamala S, Rachimi S, Verzani EK, Stevens JD, Lane WJ, Camp SY, Meli K, Pappalardi MB, Herbert ZT, Qiu X, Cejas P, Long HW, Shukla SA, Van Allen EM, Choueiri TK, Churchman LS, Abelin JG, Gurer C, MacBeath G, Childs RW, Carr SA, Keskin DB, Wu CJ, Kaelin WG Jr.  HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy.  Cell. 2025 Feb 25:S0092-8674(25)00156-4. doi: 10.1016/j.cell.2025.01.046. Online ahead of print.  PMID: 40023154

Stransky LA, Gao W, Schmidt LS, Bi K, Ricketts CJ, Ramesh V, James A, Difilippantonio S, Ileva L, Kalen JD, Karim B, Jeon A, Morgan T, Warner AC, Turan S, Unite J, Tran B, Choudhari S, Zhao Y, Linn DE, Yun C, Dhandapani S, Parab V, Pinheiro EM, Morris N, He L, Vigeant SM, Pignon JC, Sticco-Ivins M, Signoretti S, Van Allen EM, Linehan WM, Kaelin WG Jr. Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: Initial experience and lessons learned.  Proc Natl Acad Sci U S A. 2024 Oct 8;121(41):e2408549121. doi: 10.1073/pnas.2408549121. Epub 2024 Oct 4.  PMID: 39365820 
​
Abu-Remaileh M, Persky NS, Lee Y, Root DE, Kaelin WG Jr.  Total loss of VHL gene function impairs neuroendocrine cancer cell fitness due to excessive HIF2α activity.  Proc Natl Acad Sci U S A. 2024 Oct;121(40):e2410356121. doi: 10.1073/pnas.2410356121. Epub 2024 Sep 25.  PMID: 39320914 Free PMC article. 

​Lampson BL, Ramίrez AS, Baro M, He L, Hegde M, Koduri V, Pfaff JL, Hanna RE, Kowal J, Shirole NH, He Y, Doench JG, Contessa JN, Locher KP, Kaelin WG Jr.  Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κB. Cell. 2024 Apr 25;187(9):2209-2223.e16. doi: 10.1016/j.cell.2024.03.022.  PMID: 38670073​
 
Wyant GA, Jiang Q, Singh M, Qayyum S, Levrero C, Maron BA, Kaelin WG Jr.  Induction of DEPP1 by HIF Mediates Multiple Hallmarks of Ischemic Cardiomyopathy. Circulation. 2024 Jun 17. doi: 10.1161/CIRCULATIONAHA.123.066628. Online ahead of print. PMID: 38881449
 
Shi DD, Lee JH, Wang AC, Khanal J, Gao W, Kaelin WG Jr, McBrayer SK. Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma.  STAR Protoc. 2023 May 6;4(2):102281. doi: 10.1016/j.xpro.2023.102281. Online ahead of print.  PMID: 37149859 Free PMC article.
 
Shirole NH, Kaelin WG Jr. von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.  Hematol Oncol Clin North Am. 2023 Oct;37(5):809-825. doi: 10.1016/j.hoc.2023.04.011. Epub 2023 Jun 1.  PMID: 37270382 Review.
 
Shi DD, Kaelin WG.  The INDIGO trial: Precision medicine finally comes to glioma.  Neuro Oncol. 2023 Nov 2;25(11):1918-1919. doi: 10.1093/neuonc/noad162.  PMID: 37698505 No abstract available.
 
Wyant GA, Yu W, Doulamis IP, Nomoto RS, Saeed MY, Duignan T, McCully JD, Kaelin WG Jr.  Mitochondrial remodeling and ischemic protection by G protein-coupled receptor 35 agonists.   Science. 2022 Aug 5;377(6606):621-629. doi: 10.1126/science.abm1638. Epub 2022 Aug 4. PMID: 35926043  PMCID: PMC9639781
​
Shi DD, Savani MR, Levitt MM, Wang AC, Endress JE, Bird CE, Buehler J, Stopka SA, Regan MS, Lin YF, Puliyappadamba VT, Gao W, Khanal J, Evans L, Lee JH, Guo L, Xiao Y, Xu M, Huang B, Jennings RB, Bonal DM, Martin-Sandoval MS, Dang T, Gattie LC, Cameron AB, Lee S, Asara JM, Kornblum HI, Mak TW, Looper RE, Nguyen QD, Signoretti S, Gradl S, Sutter A, Jeffers M, Janzer A, Lehrman MA, Zacharias LG, Mathews TP, Losman JA, Richardson TE, Cahill DP, DeBerardinis RJ, Ligon KL, Xu L, Ly P, Agar NYR, Abdullah KG, Harris IS, Kaelin WG Jr, McBrayer SK.  De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.  Cancer Cell. 2022 Aug 12:S1535-6108(22)00324-5. Doi 10.1016/j.ccell.2022.07.011. Online ahead of print.  PMID: 35985343   PMCID: PMC9515386
 
Stransky LA, Vigeant SM, Huang B, West D, Denize T, Walton E, Signoretti S, Kaelin WG Jr.  Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.  Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119. doi: 10.1073/pnas.2120403119. Epub 2022 Mar 31. PMID: 35357972   PMCID: PMC9168943